PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Neoadjuvant tamoxifen + goserelin (premenopausal women)|DRUG: Neoadjuvant letrozole (postmenopausal women)|DRUG: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|DRUG: Neoadjuvant docetaxel + cyclophosphamide|DRUG: Neoadjuvant docetaxel|DRUG: Neoadjuvant docetaxel + trastuzumab + pertuzumab|DRUG: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|DRUG: Neoadjuvant olaparib|DRUG: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|PROCEDURE: Breast conserving surgery or mastectomy + SNB/axillary dissection|RADIATION: Postoperative radiotherapy breast/chest wall + regional lymph nodes|DRUG: Adjuvant trastuzumab|DRUG: Adjuvant letrozole (postmenopausal women)|DRUG: Adjuvant tamoxifen + goserelin (premenopausal women)|DRUG: Adjuvant palbociclib (if palbociclib given neoadjuvant)|DRUG: Adjuvant Epirubicin+ Cyclophosphamide
Sponsor: Haukeland University Hospital
Collaborators: Helse Vest|Pfizer|AstraZeneca